Tower Research Capital (TRC)’s Unicycive Therapeutics UNCY Stock Holding History
Bought
Maintained
Sold
Other funds holding UNCY
Tower Research Capital (TRC)'s UNCY Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Unicycive Therapeutics (UNCY) stake by 72% in Q3 2026, buying an estimated $6.72K and bringing the position to 3,084 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3993.
Tower Research Capital (TRC) first reported a position in UNCY in Q1 2022 and has held it in 15 quarters since. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.
- Tower Research Capital (TRC) held 3,084 shares of Unicycive Therapeutics worth $14.5K as of Q3 2026.
- Tower Research Capital (TRC) bought 1,296 Unicycive Therapeutics shares in Q3 2026, an estimated $6.72K.
- Unicycive Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3993 holding.
- Tower Research Capital (TRC) first reported a position in Unicycive Therapeutics in Q1 2022 and has held it in 15 quarters since.
- 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.